Background There is evidence that angiotensin-converting enzyme inhibitors (ACEI) and angiotensin-II receptor blockers (ARB) may reduce cardiovascular (CV) risk in patients undergoing peritoneal dialysis (PD), but no studies have compared the effectiveness between these drug classes. In this observational cohort study, we compared the association of ARB vs. ACEI use on CV outcomes in patients initiating PD. Methods We identified from the US Renal Data System all adult patients who initiated PD from 2007 to 2011 and participated in Medicare Part D, a federal prescription drug benefits program, for the first 90 days of dialysis. Patients who filled a prescription for an ACEI or ARB in those 90 days were considered users. We excluded patients who used both ACEI and ARB. We applied Cox proportional hazards regression to an inverse probability of treatment-weighted cohort to estimate the hazard ratios (HR) for the combined outcome of all-cause death, ischemic stroke, or myocardial infarction; all-cause mortality; and CV death. Results Among 1892 patients using either drug class, 39 % were ARB users. We observed 624 events over 2,898 personyears of follow-up, for a composite event rate of 22 events per 100 person-years. We observed no differences between ARB vs. ACEI users: composite outcome HR 0.94, 95 % confidence interval (CI) 0.79-1.11; all-cause mortality HR 0.92, 95 % CI 0.76-1.10; CV death HR: 1.06, 95 % CI 0.80-1.41. Conclusion We identified no significant difference in the risks of CV events or death between users of ARBs vs. ACEIs in patients initiating PD, thus supporting their mostly interchangeable use in this population.
Introduction
Cardiovascular (CV) disease is the leading cause of death among patients with end-stage kidney disease (ESKD) on maintenance dialysis [1] . While angiotensin-converting enzyme inhibitors (ACEI) and angiotensin-II receptor blockers (ARB) are recommended for the reduction of CV events for certain populations without ESKD, there is evidence that these agents may reduce the risk of CV events in patients on maintenance dialysis as well [2] [3] [4] [5] [6] [7] [8] [9] . In fact, guidelines recommend the use of either ACEI or ARB as a first-line anti-hypertensive for those with diabetic nephropathy with proteinuria and for patients on dialysis with residual kidney function, and suggest use of either ACEI or ARB for normotensive patients on peritoneal dialysis (PD) with residual kidney function [10, 11] . Notably, the guidelines recommend these two classes of medications equally (ARBs are certainly preferred for patients with ACEI-induced side effects, such as cough). However, ACEI and ARB block the renin-angiotensin system through different mechanisms and thus may not have the same effects. Yet, there is only one study on the comparative effectiveness of ARB vs. ACEI in patients on hemodialysis, and none in patients on PD [12] .
In this observational cohort study, we sought to address this evidence gap by comparing the associations of ARB vs. ACEI use on CV outcomes in patients initiating PD.
Methods Study population
We identified from the US Renal Data System all adult patients who initiated dialysis between January 1, 2007 and October 2, 2011 and were stable on PD (i.e., on the modality for at least 60 days) by day 90 of dialysis, the index date (Fig. 1) . Thus, index dates ranged from April 1, 2007 to December 31, 2011 . Inclusion criteria also included continuous Medicare (a federal health insurance program for people who are 65 or older, certain younger people with disabilities, and people with end-stage kidney disease) Parts A, B, and D coverage from day 1-90 of dialysis, and having filled at least one prescription for either an ACEI or ARB during those 90 days. We excluded patients who had filled prescriptions for both ACEI and ARB during that baseline window.
ACEI/ARB use
Use of ARB (vs. ACEI use) was the exposure of interest and defined using Medicare Part D claims. Prescription claims contain not only the generic substance and dose, but also the number of days of drug supply dispensed. Patients were categorized as ARB or ACEI users if they filled a prescription for either an ARB or ACEI, respectively, within 90 days of initiating dialysis. We excluded patients who had filled prescriptions for both ACEI and ARB. For analyses using an approach that corresponds to an ''intention-to-treat'' analysis in trials, baseline exposure was carried forward indefinitely. ''As-treated'' analyses considered patients exposed for 60 days after the recorded supply from their previously filled prescription was exhausted (''refill grace period''). If patients failed to fill a subsequent prescription during this 60-day grace period, the follow-up time was censored. Follow-up for ARB users was also censored when an ACEI prescription was filled, and vice versa.
Outcomes
For the survival analyses, the primary outcome was a composite of death from any cause, ischemic stroke, and myocardial infarction. We also analyzed all-cause mortality and CV death as separate events of interest. Non-fatal outcomes were ascertained from validated claims-based algorithms [13, 14] . Death and cause-specific mortality were ascertained from the USRDS death file as shown in the table (Online Resource 1).
Patient Characteristics
We ascertained demographics [age, sex, race (white, black, other), Hispanic ethnicity, Medicaid (a federal health insurance program for low-income patients) at time of dialysis initiation], comorbidities, body mass index (BMI) and laboratory measurements (hemoglobin, albumin, estimated glomerular filtration rate [eGFR]), baseline medication use, dialysis characteristics (year initiated dialysis, pre-dialysis referral to nephrologist, PD modality), and facility characteristics (size of the PD program, rural/urban
Exclude patients who filled a prescription for both an ACEI and ARB from day 1-90 of diaysis.
N=1,892
Restrict to patients who filled at least one prescription for an ACEI or ARB during day 1-90 of diaysis.
N=2,063
Adult [15] . Facilities were categorized into one of nine U.S. Census Bureau Divisions based on their state [16] . Details about the comorbidity algorithms have been previously described and can be found in Online Resource 2 [17, 18] .
Statistical analysis
We tabulated the characteristics of ARB and ACEI users using percentages and means (±standard deviations) or medians (interquartile range). We compared the two groups using standardized differences, with differences [10 indicating unacceptable imbalance between the two groups [19] .
We conducted an inverse probability of treatment weighted (IPTW) survival analysis, a novel method to control for selection bias by observed characteristics between ARB users and ACEI users [20] . We fit a logistic regression model of ARB vs. ACEI use using all available baseline characteristics (Table 1) and calculated each patient's expected probability of receiving an ARB by combining his or her covariate vector with the corresponding coefficients of the model. Patients were then weighted by the inverse of their expected probability of using an ARB for those actually receiving an ARB, and the inverse of the expected probability of using an ACEI for those actually receiving an ACEI, to create a pseudopopulation with similar percentage of patients exposed to one drug class versus the other in each level of the covariates as the overall percentage in the study population. This way, balance ideally achieved in a randomized study is being simulated, albeit solely for observed characteristics. Since vital signs and laboratory measurements were not available for all patients, we did not use these variables in estimating treatment probabilities. However, note that we still achieved balance in the IPTW cohort for these vital signs and laboratory measurements. Please see Online Resource 3 for detailed information on this method.
To exclude the differential use of direct renin inhibitors (i.e. aliskiren) as a potential confounder, we conducted a sensitivity analysis excluding patients who were prescribed this class of medications. To test whether short followtimes may have biased the results, we also ran sensitivity analyses restricting the cohort to patients we had remained on PD event-free for at least a year.
All survival analyses were conducted using Cox proportional hazard regression with robust standard errors. As patients may have had multiple events, we only analyzed the first event they experienced. Patients were censored on end of database (January 1, 2012). For as-treated analyses, patients were additionally censored for discontinuation of Part D, on the 61st day after their most recent recorded prescription expired and had not been refilled, for ARB users when an ACEI prescription was filled, and for ACEI users when an ARB prescription was filled. Violation of the proportional hazards assumption was checked using interaction terms with time. All hazard ratios (HR) were accompanied by their corresponding 95 % confidence interval (CI).
All analyses were performed using SAS Enterprise Guide 6.1 (SAS Institute Inc., Cary, NC, USA). Institutional Review Boards of Baylor College of Medicine, Los Angeles Biomedical Institute at Harbor-UCLA Medical Center, and Stanford University approved the study.
Results
Of the 4949 patients who initiated peritoneal dialysis from 2007 to 2011 and who satisfied all eligibility criteria, 2063 (42 %) used either an ACEI or ARB; 171 filled prescriptions for both drug classes and were removed from consideration. Of the remaining 1892 patients, 741 (39 %) were ARB users and 1151 (61 %) were ACEI users. Several baseline characteristics differed between the two treatment groups: ARB users were older and more likely to be female than ACEI users (Table 1) . They were also more likely to have seen a nephrologist prior to dialysis initiation and used diuretics, though the dose of diuretics prescribed was no different than that prescribed to ACEI users. ARB users were less likely to have heart failure or to have been hospitalized in the first 90 days of dialysis. After weighting the cohort by their inverse probability of treatment with ARB, all observed characteristics were balanced between ARB users and ACEI users (Table 1) .
In the intention-to-treat analyses, we observed 624 composite events (death, stroke, or myocardial infarction) over 2898 person-years of follow-up, for a composite event rate of 21.5 events per 100 person-years. There were 17.7 deaths, and 6.8 CV deaths per 100 person-years. The observed rates of all outcomes were no different between ARB and ACEI users, and the confidence intervals accompanying all HR of interest crossed the null value, indicating no associations between drug class and outcomes ( Table 2 ). The ''as treated'' analyses yielded similar results.
To exclude the use of direct renin inhibitors as a potential confounder, we repeated the analyses excluding 22 patients who were prescribed direct renin inhibitors. The hazard ratios and 95 % confidence intervals were unchanged from the primary analysis.
To test whether short follow-up times may have biased the results of the primary analysis, we also repeated the analyses restricting the cohort to patients who had remained on PD event-free for at least a year. The results were materially the same as those from the primary analysis (Table 2) .
Discussion
In this large, population-based cohort of patients initiating PD, we did not find any significant differences in the risks of CV events, CV death, or all-cause mortality when comparing those using an ARB vs. ACEI. Previous studies have shown an association between ACEI or ARB (vs. no use) and a reduction in CV events in patients on PD [5, 21] , but, to our knowledge, ours is the first to compare the two classes of medications in PD patients.
There are plausible reasons why ACEI could potentially be more beneficial than ARB. ACEI increase the level of bradykinin and improve endothelial function, which is often impaired in patients on dialysis [22] [23] [24] [25] . Meta-analyses have not consistently found one class to be superior to the other in reducing CV outcomes in patients not on dialysis [26] [27] [28] [29] [30] [31] . Owing to the paucity of randomized clinical trial data of ACEI and ARB in patients on maintenance dialysis, no comparable meta-analysis has been conducted in the dialysis population, and only one observational cohort study of 22,628 patients on maintenance hemodialysis has addressed the issue. That study also found no difference in CV outcomes between users of ARB vs. ACEI (adjusted HR 0.96, 95 % CI 0.89-1.04) [12] . Still, patients on PD differ from those on hemodialysis in that they are regularly exposed to dextrose-containing PD solution. ACEI may lead to a kinin-mediated increase in insulin sensitivity not seen with ARB [32] . This could potentially lower the CV risk in patients on PD who are subjected to high glucose loads that may lead to insulin resistance and its associated CV risk [33] . However, our study suggests that, similar to that observed in patients on hemodialysis, this theoretical advantage does not translate into a clinical benefit of using ACEI instead of ARB for improving CV outcomes of patients on PD. This lends further credence to the clinical guidelines that currently recommend the two classes of medication equally.
Our study has limitations, including the inability to control for unmeasured confounders such as blood pressure, residual kidney function, serum potassium levels, markers of mineral metabolism, the specific indication for the drug (confounding by indication), and prior duration of its use. It is possible that ARB users had better controlled blood pressure, more residual kidney function, fewer instances of hyperkalemia, or better controlled mineral Table 2 Number of events, follow-up time, incidence rates, and hazard ratios for all study outcomes based on an inverse probability of treatment weighted population of ACEI users and ARB users ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin-II receptor blocker, AT as treated, CI confidence interval, ITT intention to treat, SD standard deviation a Cohort for this analysis was restricted to those who had been on peritoneal dialysis for at least 1 year event-free b Note that follow-up for the C1 year on PD cohort began on day 455 of dialysis whereas in the other analyses follow-up began on day 90 of dialysis. Thus, patients in the C1 year on PD cohort were followed on average until day 930 of dialysis whereas patients in the ITT analysis of the full cohort were followed on average until day 652 of dialysis metabolism and that this outweighed any potential benefit of ACEI use. It is also possible that some ARB users were previously on ACEI pre-dialysis, and that this prior ACEI use rather than the proximate ARB use was driving the results. We also did not have data on scheduled visits after initiation of drug treatment. Thus, it is possible that the ARB group had closer follow-up with a physician which led to lower rates of hypotension and hyperkalemia which in turn improved survival. This scenario is unlikely, though, since visit frequency correlates with facility characteristics, and the facilities were similar in the two groups [34] . Because our cohort was restricted to those receiving Medicare Part D when they initiated PD, the results may not be generalizable to those who do not qualify for this drug benefit, a group that tends to be younger. While the sample size was relatively large for such a study, the confidence limits were too wide to exclude clinically meaningful differences of moderate size. These limitations need to be considered in light of the strengths of the study, which include a large incident cohort of patients on PD with a high burden of comorbidities, a group that is usually excluded from clinical trials.
In conclusion, we did not find any differences in the rates of CV events or death from any cause with the use of an ARB vs. ACEI in patients initiating PD, suggesting that both may be equally effective in reducing CV outcomes in this population.
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